Forecasts data is unavailable for this security.

Consensus recommendation

As of Aug 26, 2016, the consensus forecast amongst 30 polled investment analysts covering AstraZeneca plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Jan 20, 2016. The previous consensus forecast advised investors to hold their position in AstraZeneca plc.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy5
Outperform10
Hold11
Underperform3
Sell0

Research reports

More ▼

Dividends

In 2015, AstraZeneca PLC reported a dividend of 2.80 USD, equaling last years dividend. The 28 analysts covering the company expect dividends of 2.82 USD for the upcoming fiscal year, an increase of 0.57%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates

On Jul 28, 2016, AstraZeneca plc reported 2nd quarter 2016 earnings of 0.83 per share. This result was in line with the consensus of the 18 analysts following the company and under-performed last year's 2nd quarter results by 30.83%.
The next earnings announcement is expected on Nov 10, 2016.
Average growth rate-8.62%
AstraZeneca plc reported annual 2015 earnings of 4.26 per share on Feb 04, 2016.
Average growth rate-12.22%
More ▼

Revenue history & estimates

AstraZeneca PLC had 2nd quarter 2016 revenues of 5.60bn. This bettered the 5.57bn consensus of the 17 analysts covering the company. This was 11.16% below the prior year's 2nd quarter results.
Average growth rate-2.80%
AstraZeneca PLC had revenues for the full year 2015 of 23.64bn. This was 9.40% below the prior year's results.
Average growth rate-8.18%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.